May 19, 2023 — Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, announced the introduction of the Actionable Clinical Intelligence (ACI) platform to expand the information available to clinicians prescribing the Epi+Gen CHD and PrecisionCHD laboratory developed tests (LDTs). ACI offers new data-driven insights into the epigenetic and genetic molecular underpinnings of coronary heart disease (CHD).
Epi+Gen CHD and PrecisionCHD are artificial intelligence (AI)-driven integrated epigenetic-genetic LDTs for the risk assessment and detection of CHD, respectively. ACI’s analytics framework integrates LDT results with a patient’s unique epigenetic and genetic biomarkers and clinical information to provide deeper and actionable insights to clinicians about factors driving the patient’s CHD. Such insights include the relative contribution of each of the patient’s biomarkers to CHD, evidence on the role of these biomarkers in CHD pathogenesis, and changes in the measured biomarkers over time in response to lifestyle and therapeutic interventions. These evidence-based insights are tailored to each patient to help elucidate areas of concern and aid a clinician’s independent assessment, with the goal of improving patient outcomes.
“With ACI, we are expanding the tools available to healthcare providers, enabling them to make personalized, data-driven decisions that are informed by a patient's unique genetic and epigenetic profile. Empowering clinicians with insights, such as those offered by ACI, furthers our pursuit to help improve patient outcomes towards realizing a future where heart disease can be more effectively prevented, managed, and treated”, shared Tim Dogan, Ph.D., Chief Technology Officer of Cardio Diagnostics.
In addition to providers, ACI also has the potential to benefit health plans and employers. Health plans can leverage personalized insights from ACI to risk stratify and identify individuals in need of additional interventions; these heightened and targeted interventions may serve to reduce costly utilization and avoidable hospitalizations and help improve chronic care management, thereby potentially reducing healthcare costs. For employers, adding the PrecisionCHD and Epi+Gen CHD tests with ACI into employee wellness programs may promote proactive management of factors contributing to CHD, which could improve overall employee health, reduce absenteeism, and lower healthcare expenditures.
Meesha Dogan, Ph.D., CEO and Co-Founder at Cardio Diagnostics, remarked, "Cardio Diagnostics remains steadfast in its commitment to driving innovation in cardiovascular medicine. The launch of Actionable Clinical Intelligence marks a significant milestone in our mission to revolutionize the prevention, management, and treatment of coronary heart disease. With ACI, clinicians now have novel and actionable molecular insights about their patients beyond proxy biomarkers for heart disease, such as cholesterol and blood pressure. Many at risk for or who already have coronary heart disease do not have traditional risk factors, signs, and symptoms. By harnessing the power of epigenetics, genetics, and AI, we now have the ability to personalize the management and treatment of heart disease at the molecular level, where biology happens. That is the promise of Precision Cardiovascular Medicine."
For more information: www.cardiodiagnosticsinc.com
April 18, 2024 
